IE
FULC icon

Israel Englander’s Fulcrum Therapeutics FULC Stock Holding History

Israel Englander’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-35,000
Closed -$828K – 7136
2022
Q1 		$828K Buy
+35,000
New +$495K ﹤0.01% 4714

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Israel Englander's FULC Position: Q2 2026 in Review

Israel Englander increased its Fulcrum Therapeutics (FULC) stake by 317% in Q2 2026, buying an estimated $6.87M and bringing the position to 1,485,803 shares worth $5.44M. The position accounts for ﹤0.01% of the portfolio, ranked #2921.

Israel Englander first reported a position in FULC in Q3 2019 and has held it in 24 quarters since. The position peaked at $8.47M in Q1 2024. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Israel Englander held 1,485,803 shares of Fulcrum Therapeutics worth $5.44M as of Q2 2026.
  • Israel Englander bought 1,129,332 Fulcrum Therapeutics shares in Q2 2026, an estimated $6.87M.
  • Fulcrum Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2921 holding.
  • Israel Englander first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 24 quarters since.
  • Israel Englander's Fulcrum Therapeutics position peaked at $8.47M in Q1 2024.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.